title: One year duration of immunity of the modified live bovine viral diarrhea virus type 1 and type 2 and bovine herpesvirus-1 fractions of Vista® Once SQ vaccine.
abstract: Three studies were performed to determine the duration of immunity of the bovine viral diarrhea virus type 1 and type 2 (BVDV-1 and BVDV-2) and bovine herpesvirus-1 (BHV-1) fractions of a commercially prepared modified-live vaccine. Vista® Once SQ (Vista®) vaccine contains five modified-live viruses, BVDV-1, BVDV-2, BHV-1, bovine respiratory syncytial virus, and bovine parainfluenza 3 virus, and two modified-live bacteria, Pasteurella multocida and Mannheimia haemolytica. For all three studies, calves were administered a single dose of vaccine or placebo vaccine subcutaneously, and were challenged with one of the three virulent viruses at least one year following vaccination. Calves were evaluated daily following challenge for clinical signs of disease associated with viral infection, nasal swab samples were evaluated for virus shedding, and serum was tested for neutralizing antibodies. Following the BVDV-1 and BVDV-2 challenges, whole blood was evaluated for white blood cell counts, and for the BVDV-2 study, whole blood was also evaluated for platelet counts. Calves vaccinated with BVDV type 1a, were protected from challenge with BVDV type 1b, and had significant reductions in clinical disease, fever, leukopenia, and virus shedding compared to control calves. Vaccinated calves in the BVDV-2 study were protected from clinical disease, mortality, fever, leukopenia, thrombocytopenia, and virus shedding compared to controls. Vaccinated calves in the BHV-1 study were protected from clinical disease and fever, and had significantly reduced duration of nasal virus shedding. These three studies demonstrated that a single administration of the Vista® vaccine to healthy calves induces protective immunity against BVDV-1, BVDV-2 and BHV-1 that lasts at least one year following vaccination.
authors: Merck Animal Health, 35500 W. 151st St., De Soto, KS 66062, USA. Electronic address: lisa.purtle@merck.com.
authors: Lisa
authors: L
authors: Purtle
authors: Merck Animal Health, 35500 W. 151st St., De Soto, KS 66062, USA.
authors: Debra
authors: D
authors: Mattick
authors: Merck Animal Health, 35500 W. 151st St., De Soto, KS 66062, USA.
authors: Corey
authors: C
authors: Schneider
authors: Merck Animal Health, 35500 W. 151st St., De Soto, KS 66062, USA.
authors: Linda
authors: L
authors: Smith
authors: Merck Animal Health, 35500 W. 151st St., De Soto, KS 66062, USA.
authors: Wenzhi
authors: W
authors: Xue
authors: Merck Animal Health, 35500 W. 151st St., De Soto, KS 66062, USA.
authors: Emilio
authors: E
authors: Trigo
mesh_terms: D000818:Animals; D057134:Antibodies, Neutralizing / Q000097:blood; D000914:Antibodies, Viral / Q000097:blood; D001912:Bovine Virus Diarrhea-Mucosal Disease / Q000517:prevention & control*; D002417:Cattle; D030241:Diarrhea Virus 1, Bovine Viral; D030242:Diarrhea Virus 2, Bovine Viral; D006566:Herpesviridae Infections / Q000517:prevention & control / Q000662:veterinary*; D007242:Herpesvirus 1, Bovine; D009500:Neutralization Tests; D014611:Vaccination / Q000662:veterinary*; D014613:Vaccines, Attenuated / Q000276:immunology; D014765:Viral Vaccines / Q000276:immunology*; D017201:Virus Shedding
chemical_list: D057134:Antibodies, Neutralizing; D000914:Antibodies, Viral; D014613:Vaccines, Attenuated; D014765:Viral Vaccines
keywords: BHV; BVDV; Efficacy; Immunity; Modified-live; Vaccine